三阴乳腺癌分型及其药物治疗  

Classification and Drug Treatment of Triple-negative Breast Cancer

作　　者：李芮蝶 朱雪莉 陈鑫[1] LI Rui-die;ZHU Xue-li;CHEN Xin(Endocrine and Breast Surgery,the First Affiliated Hospital of Chongqing Medical University,Chongqing 400016,China)

机构地区：[1]重庆医科大学附属第一医院内分泌乳腺外科,重庆400016

出　　处：《医学信息》2020年第5期40-44,共5页Journal of Medical Information

摘　　要：乳腺癌是女性最常见的癌症之一,其中三阴乳腺癌(TNBC)作为其特殊亚型,具有发病年龄早、复发率高、早期转移率高、侵袭性强、预后差等特点,由于缺乏相应的雌、孕激素受体及明确的分子靶点,传统的内分泌及靶向治疗对其均不敏感,引起全球学者越来越多的关注。随着一些药物作用靶点的发现,结合三阴乳腺癌的高免疫原性及特殊的生物学异质性,免疫治疗及新型靶向治疗前景可观。本文就TNBC分型及药物治疗作一综述,以期为TNBC患者临床治疗提供参考。Breast cancer is one of the most common cancers in women.Among them,triple negative breast cancer(TNBC)is a special subtype of breast cancer.Corresponding estrogen and progesterone receptors and clear molecular targets,traditional endocrine and targeted therapies are not sensitive to it,causing more and more attention from scholars worldwide.With the discovery of some drug action targets,combined with the high immunogenicity and special biological heterogeneity of triple negative breast cancer,immunotherapy and new targeted therapies have promising prospects.This article reviews the TNBC classification and drug treatment,with a view to providing reference for clinical treatment of TNBC patients.

关 键 词：三阴乳腺癌 亚型 药物治疗 靶向治疗 免疫治疗 

分 类 号：R737.9[医药卫生—肿瘤]